Tau and Ab imaging, CSF measures, and cognition in Alzheimer's disease

Matthew R. Brier, Brian Gordon, Karl Friedrichsen, John McCarthy, Ari Stern, Jon Christensen, Christopher Owen, Patricia Aldea, Yi Su, Jason Hassenstab, Nigel J. Cairns, David M. Holtzman, Anne M. Fagan, John C. Morris, Tammie L.S. Benzinger, Beau M. Ances

Research output: Contribution to journalArticlepeer-review

274 Scopus citations

Abstract

Alzheimer's disease (AD) is characterized by two molecular pathologies: cerebral b-Amyloidosis in the form of b-Amyloid (Ab) plaques and tauopathy in the form of neurofibrillary tangles, neuritic plaques, and neuropil threads. Until recently, only Ab could be studied in humans using positron emission tomography (PET) imaging owing to a lack of tau PET imaging agents. Clinical pathological studies have linked tau pathology closely to the onset and progression of cognitive symptoms in patients with AD. We report PET imaging of tau and Ab in a cohort of cognitively normal older adults and those with mild AD. Multivariate analyses identified unique disease-related stereotypical spatial patterns (topographies) for deposition of tau and Ab. These PET imaging tau and Ab topographies were spatially distinct but correlated with disease progression. Cerebrospinal fluid measures of tau, often used to stage preclinical AD, correlated with tau deposition in the temporal lobe. Tau deposition in the temporal lobe more closely tracked dementia status and was a better predictor of cognitive performance than Ab deposition in any region of the brain. These data support models of AD where tau pathology closely tracks changes in brain function that are responsible for the onset of early symptoms in AD.

Original languageEnglish
Article number338ra66
JournalScience translational medicine
Volume8
Issue number338
DOIs
StatePublished - May 11 2016

Fingerprint Dive into the research topics of 'Tau and Ab imaging, CSF measures, and cognition in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this